AB0024
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neoplasms
Conditions
Neoplasms
Trial Timeline
Jun 1, 2010 → Mar 1, 2012
NCT ID
NCT01323933About AB0024
AB0024 is a phase 1 stage product being developed by Gilead Sciences for Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT01323933. Target conditions include Neoplasms.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01323933 | Phase 1 | Completed |
Competing Products
20 competing products in Neoplasms